Is JAK2V617F Mutation the Only Factor for Thrombosis in Philadelphia-Negative Chronic Myeloproliferative Neoplasms?

Creative Commons License

UYANIK M. Ş., BAYSAL M., PAMUK G. E., MADEN M., AKKER M., ÜMİT E. G., ...Daha Fazla

Indian Journal of Hematology and Blood Transfusion, cilt.32, sa.3, ss.262-267, 2016 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 32 Sayı: 3
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1007/s12288-015-0578-2
  • Dergi Adı: Indian Journal of Hematology and Blood Transfusion
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.262-267
  • Anahtar Kelimeler: Allele burden, Chronic myeloproliferative neoplasms, JAK2 mutation, Thrombosis
  • Trakya Üniversitesi Adresli: Evet

Özet

The most common genetic disorder in Philadelphia negative chronic myeloproliferative neoplasms is the JAK2-V617F mutation. In the present study, we aimed to determine risk factors for thrombosis in patients with essential thrombocytosis and polycythemia vera. We screened the medical records of 101 patients. Risk factors which may predict thrombosis were recorded. Venous thrombosis (VT) before diagnosis was significantly higher in JAK2 positive patients. VT after diagnosis was similar in JAK2 positive and negative groups, and was significantly higher in elderly patients. Treatment places importance on the JAK2 mutation under unmodifiable cardiovascular risk factors such as advanced age after diagnosis.